Circulating Tumor DNA as a Prognostic Marker in Patients With Pancreatic Cancer
NCT03214991 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2018-02-05
Summary
The aim of this study is to determine the usefulness of circulating tumor DNA as a prognostic factor in patients with pancreatic cancer.
Conditions
Sponsors & Collaborators
-
Ji Kon Ryu
lead OTHER
Principal Investigators
-
Ji Kon Ryu, MD, PhD · Seoul National University Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-05-12
- Primary Completion
- 2020-09-30
- Completion
- 2021-03-31
Countries
- South Korea
Study Locations
More Related Trials
-
Biomarker Analysis of Solid Cancers Such as Gastrointestinal Cancer
NCT01831609 ·Status: UNKNOWN
-
ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer
NCT07151118 ·Status: RECRUITING
-
Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer
NCT00899405 ·Status: RECRUITING
-
The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of Pancreatic Cancer
NCT06497777 ·Status: RECRUITING
-
Circulating Epigenetics in Pancreatic Surgery
NCT04947696 ·Status: UNKNOWN
-
AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Hepatobiliary Cancer Malignancies
NCT04835675 ·Status: COMPLETED
-
Circulating DNA in Surgically Treated NSCLC
NCT04037150 ·Status: UNKNOWN
-
Observational Study of ctDNA in Resectable and Borderline Resectable Pancreatic Cancer
NCT05379907 ·Status: WITHDRAWN
-
Use of Ctdna in Patients With Gastrointestinal Tract Tumors
NCT06202131 ·Status: RECRUITING
-
Circulating Cell-free DNA as a Predictive Biomarker for Hepatocelluar Carcinoma.
NCT02036216 ·Status: UNKNOWN
-
Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer
NCT02790944 ·Status: COMPLETED
-
Real-time Monitoring of Concentration and Size Variations of Circulating Plasma Free DNA to Predict Early Response to Immunotherapies in Patients With Different Types of Cancer.
NCT05083494 ·Status: UNKNOWN
-
Liquid Biopsy in Monitoring the Therapeutic Efficacy of Targeted Therapy in Advanced/Metastatic Gastric Cancer
NCT02610218 ·Status: UNKNOWN
-
DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer
NCT02079363 ·Status: UNKNOWN
-
Cohort Study of Pancreatic Cancer Risk
NCT04247503 ·Status: ACTIVE_NOT_RECRUITING
-
Circulating Free DNA Analysis in Gastrointestinal Cancer, Genitourinary Cancer, Rare Cancer
NCT02067754 ·Status: COMPLETED
-
U01-Biomarkers for Noninvasive and Early Detection of Pancreatic Cancer
NCT03886571 ·Status: UNKNOWN
-
Plasma Circulating Deoxyribonucelic Acid (DNA) as a Response Marker
NCT00318604 ·Status: UNKNOWN
-
Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC
NCT03302325 ·Status: COMPLETED
-
Potential Clinical Utilities of Circulating Tumor DNA in Advanced HER2 Negative Gastric Cancer
NCT05513144 ·Status: UNKNOWN
-
Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection
NCT05585684 ·Status: RECRUITING
-
Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients
NCT00213798 ·Status: COMPLETED ·Phase: NA
-
Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients
NCT05343832 ·Status: UNKNOWN
-
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
NCT05600933 ·Status: ENROLLING_BY_INVITATION
-
Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC
NCT07142226 ·Status: RECRUITING